Cambridge, UK, Oct 03 2022: o2h Discovery is pleased to announce Kuano as a winner of the o2h Kickstarter competition. Kuano has developed a quantum simulation platform to calculate the structure of proteins during their transition state in order to design new drugs.
As part of the kickstarter programme, o2h Discovery will be providing small molecule synthetic chemistry support to their oncology focused research programmes. o2h Discovery more broadly will also support assay development, screening and ADME.
Kuano is focusing on developing enzyme inhibitors using artificial intelligence and quantum simulations to build a pipeline of oncology programmes. Kuano has designed and built the platform and is in the process of closing a Seed extension round prior to a Series A planned for Q3 2023. They have recently been awarded a significant non-dilutive funding award, to be announced soon.
The o2h Kickstarter Competition was launched in summer 2022 (now closed) to supercharge early-stage biotechnology companies with chemistry support. This is the second winner to be announced, the first was Nottingham University Integrin platform company Alevin Therapeutics.
Vid Stojevic, CEO & Co-Founder said: “We are really pleased to have won this competition. This will be really valuable in supporting our first commercial drug discovery and development programme to reach a valuable inflection point at which we could collaborate with big pharma or form a base for our Series A investment.”
Sunil Shah, CEO of o2h Ventures said: “We really pleased that Kuano was selected to win a kickstarter award, they have a unique and established platform that can speed up the drug discovery process to find new drugs for difficult to drug oncology targets.”
About o2h discovery:
Founded in 2005, o2h discovery is a Contract Research Organisation which has an integrated drug discovery platform operating from its state-of-the-art research centre in India and The Mill SciTech Park, Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development.
For more information about o2h Discovery, visit: https://www.o2h.com or email marketing@o2h.com
About Kuano:
Kuano is a quantum simulation driven drug discovery company based in Cambridge, UK. Kuano has developed a unique approach, based on advanced quantum simulations supported by AI, to design better drug candidates for hard to drug enzyme targets. Kuano was founded in 2020 by Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D’Oyley.
As a simulation-first company, we are focusing on cutting edge quantum and molecular simulation technologies to generate previously unattainable information which is crucial for successful drug design on enzyme targets. Our platform utilises this information in AI Design and Wet-lab Test Cycles to enable efficient search through chemical space for optimal drug candidates.
For more information visit: https://www.kuano.ai/
